OpenAI acquires Orchestra Bio to boost AI-driven life sciences research

AIAIOpenAI News

OpenAI is acquiring the biotech startup Orchestra Bio. The deal adds Orchestra's team and technology to OpenAI's Rosalind AI model and its Rosalind Workbench platform, which aim to help researchers plan experiments and analyze results in drug development. The acquisition is intended to accelerate life‑science R&D and new treatment development.

Why it matters: It expands AI tools available for biopharma research, offering developers new capabilities for experimental design and data analysis.

More in AI

AI10h ago4 sources

DeepSeek open-sources DeepInfer inference framework for V4.1-Flash model

Bloomberg Technology + 3 more

AIModel release17h ago3 sources

Cloudflare launches Clairic extraction model costing $0.10 per million tokens